Send me real-time posts from this site at my email
Motley Fool

Why Pfizer Stock Fell 10.2% in 2019

What happened

Pharmaceutical mega-titan Pfizer (NYSE: PFE) lost an eye-catching 10.2% of its value over the course of 2019, according to data from S&P Global Market Intelligence. Investors avoided this top drugmaker last year for two major reasons.

First, the drugmaker's decision to spin off its generic drug business, known as Upjohn, and merge it with Mylan, was not a big hit with Wall Street. Although this strategic move will remove a key overhang in the form of ongoing patent losses, it will also significantly reduce the company's free cash flow, lessening its firepower for value-creating business development transactions.

Second, Pfizer's top-selling pain medication, Lyrica, officially began facing generic competition in the middle of 2019. Unsurprisingly, its sales plummeted during the third quarter.

Image Source: Getty Images.

So what

Wall Street rarely likes major shake-ups, especially when they are undertaken by industry stalwarts like Pfizer. Pfizer, however, clearly needed to change course. Despite the drugmaker's successful pivot to oncology as a main growth driver, it simply hasn't been able to generate healthy levels of top-line growth on a consistent basis due to an avalanche of patent expiries. The spin-off of its generic drug business should immediately remedy that fundamental problem. In fact, management expects the company's revenues to rise by an average of 6% annually for the period from 2021 through 2025.

Now what

Is Pfizer's stock worth buying after last year's double-digit pullback? The answer is a resounding yes. The fact of the matter is that this pharmaceutical giant should be a far more compelling growth play than it has been in years past, thanks to management's decision to finally execute a much-needed split.

10 stocks we like better than Pfizer
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Pfizer wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks

*Stock Advisor returns as of December 1, 2019

George Budwell has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.


Source

Popular posts

Welcome!!! Is it your First time here?

What are you looking for? Select your points of interest to improve your first-time experience:

Apply & Continue